Sanifit logo portada

A new approach to
calcification disorders

Sanifit logo portada

A new approach to
calcification disorders

sanifit

SANIFIT

Sanifit is a biopharmaceutical company focused on treatments for calcification disorders, with SNF472 as the lead compound. The company was founded in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Palma (Spain) and San Diego (USA). SNF472 is an experimental drug in development for the treatment of cardiovascular diseases related to calcification in the End Stage Renal Disease (ESRD) population undergoing hemodialysis. In 2018 Sanifit has completed a phase II proof of concept trial in patients with calciphylaxis, which met its primary endpoint.  The company is planning to initiate a phase III study in this orphan disease in 2018. The ongoing phase IIb study (Calipso) in ESRD patients on dialysis is evaluating the effect of SNF472 on progression of arterial calcification.

ABOUT US

PROJECT SUPPORTED BY

OVERVIEW PIPELINE

LATEST NEWS

Your name (required)

Phone (required)

Company

E-mail (required)

Comments

CONTACT

Sanifit


SPAIN
ParcBIT – Ctra Valldemossa km7.4
Building Europa, 2nd floor
07121 Palma

 

 +34 971 439 925
 info@sanifit.com

USA
3655 Nobel Drive
Suite #540
San Diego, CA 92122